Cargando…

A single topical fluralaner application to cats and to dogs controls fleas for 12 weeks in a simulated home environment

BACKGROUND: Fluralaner (Bravecto®, Merck Animal Health, Madison, NJ, USA) is a novel isoxazoline that provides up to 12 weeks flea and tick control when administered orally to dogs. Two assessor-blinded studies, one in dogs, the other in cats evaluated the sustained efficacy of a topical fluralaner...

Descripción completa

Detalles Bibliográficos
Autores principales: Ranjan, Sivaja, Young, David, Sun, Fangshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029119/
https://www.ncbi.nlm.nih.gov/pubmed/29970135
http://dx.doi.org/10.1186/s13071-018-2927-0
_version_ 1783336897691516928
author Ranjan, Sivaja
Young, David
Sun, Fangshi
author_facet Ranjan, Sivaja
Young, David
Sun, Fangshi
author_sort Ranjan, Sivaja
collection PubMed
description BACKGROUND: Fluralaner (Bravecto®, Merck Animal Health, Madison, NJ, USA) is a novel isoxazoline that provides up to 12 weeks flea and tick control when administered orally to dogs. Two assessor-blinded studies, one in dogs, the other in cats evaluated the sustained efficacy of a topical fluralaner formulation against fleas in a simulated home environment (SHE). METHODS: Animals were ranked and blocked into groups of two using flea counts completed 24 hours following Ctenocephalides felis infestations placed on dogs on Day -64, and on cats on Day -36. Within blocks animals were randomized to a treatment group, 10 animals per group, one group to receive fluralaner spot-on (minimum dose rate for dogs, 25 mg/kg; for cats, 40 mg/kg), the other to be a sham-treated control. Animals were then placed into their SHE, one animal per pen or cage and then infested with 100 C. felis at weekly intervals. Dogs were infested from Day -56 through -21 and cats on Days -28 and -21. Fleas were counted and removed from each dog and cat on Day -1. Study animals were then held in clean pens/cages until treatment on Day 0. One day later, after treatment, all animals were returned to their home environment (SHE). Additional 50-flea challenges were placed on each animal on Days 22, 50 and 78. Fleas were counted and replaced on all animals on Day 1 and weekly thereafter for 12 weeks. RESULTS: Arithmetic mean counts in control-group animals exceeded 10 fleas at all post-treatment assessments except on Days 1, 7 and 14. All control-group animals remained infested at each assessment from Day or 28 through Day 84, thereby validating the challenge methodology. Fluralaner efficacy was 100% on all occasions except for 2 fleas found on 1 dog on Day 1, and 3 fleas on 1 dog on Day 14. One flea was recovered from 1 fluralaner treated cat on Day 1. There were no treatment-related adverse events. CONCLUSION: A single application of a topical formulation of fluralaner is well tolerated and highly effective in the prevention of flea infestations of dogs and cats throughout the 12 weeks following treatment.
format Online
Article
Text
id pubmed-6029119
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60291192018-07-09 A single topical fluralaner application to cats and to dogs controls fleas for 12 weeks in a simulated home environment Ranjan, Sivaja Young, David Sun, Fangshi Parasit Vectors Research BACKGROUND: Fluralaner (Bravecto®, Merck Animal Health, Madison, NJ, USA) is a novel isoxazoline that provides up to 12 weeks flea and tick control when administered orally to dogs. Two assessor-blinded studies, one in dogs, the other in cats evaluated the sustained efficacy of a topical fluralaner formulation against fleas in a simulated home environment (SHE). METHODS: Animals were ranked and blocked into groups of two using flea counts completed 24 hours following Ctenocephalides felis infestations placed on dogs on Day -64, and on cats on Day -36. Within blocks animals were randomized to a treatment group, 10 animals per group, one group to receive fluralaner spot-on (minimum dose rate for dogs, 25 mg/kg; for cats, 40 mg/kg), the other to be a sham-treated control. Animals were then placed into their SHE, one animal per pen or cage and then infested with 100 C. felis at weekly intervals. Dogs were infested from Day -56 through -21 and cats on Days -28 and -21. Fleas were counted and removed from each dog and cat on Day -1. Study animals were then held in clean pens/cages until treatment on Day 0. One day later, after treatment, all animals were returned to their home environment (SHE). Additional 50-flea challenges were placed on each animal on Days 22, 50 and 78. Fleas were counted and replaced on all animals on Day 1 and weekly thereafter for 12 weeks. RESULTS: Arithmetic mean counts in control-group animals exceeded 10 fleas at all post-treatment assessments except on Days 1, 7 and 14. All control-group animals remained infested at each assessment from Day or 28 through Day 84, thereby validating the challenge methodology. Fluralaner efficacy was 100% on all occasions except for 2 fleas found on 1 dog on Day 1, and 3 fleas on 1 dog on Day 14. One flea was recovered from 1 fluralaner treated cat on Day 1. There were no treatment-related adverse events. CONCLUSION: A single application of a topical formulation of fluralaner is well tolerated and highly effective in the prevention of flea infestations of dogs and cats throughout the 12 weeks following treatment. BioMed Central 2018-07-03 /pmc/articles/PMC6029119/ /pubmed/29970135 http://dx.doi.org/10.1186/s13071-018-2927-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Ranjan, Sivaja
Young, David
Sun, Fangshi
A single topical fluralaner application to cats and to dogs controls fleas for 12 weeks in a simulated home environment
title A single topical fluralaner application to cats and to dogs controls fleas for 12 weeks in a simulated home environment
title_full A single topical fluralaner application to cats and to dogs controls fleas for 12 weeks in a simulated home environment
title_fullStr A single topical fluralaner application to cats and to dogs controls fleas for 12 weeks in a simulated home environment
title_full_unstemmed A single topical fluralaner application to cats and to dogs controls fleas for 12 weeks in a simulated home environment
title_short A single topical fluralaner application to cats and to dogs controls fleas for 12 weeks in a simulated home environment
title_sort single topical fluralaner application to cats and to dogs controls fleas for 12 weeks in a simulated home environment
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029119/
https://www.ncbi.nlm.nih.gov/pubmed/29970135
http://dx.doi.org/10.1186/s13071-018-2927-0
work_keys_str_mv AT ranjansivaja asingletopicalfluralanerapplicationtocatsandtodogscontrolsfleasfor12weeksinasimulatedhomeenvironment
AT youngdavid asingletopicalfluralanerapplicationtocatsandtodogscontrolsfleasfor12weeksinasimulatedhomeenvironment
AT sunfangshi asingletopicalfluralanerapplicationtocatsandtodogscontrolsfleasfor12weeksinasimulatedhomeenvironment
AT ranjansivaja singletopicalfluralanerapplicationtocatsandtodogscontrolsfleasfor12weeksinasimulatedhomeenvironment
AT youngdavid singletopicalfluralanerapplicationtocatsandtodogscontrolsfleasfor12weeksinasimulatedhomeenvironment
AT sunfangshi singletopicalfluralanerapplicationtocatsandtodogscontrolsfleasfor12weeksinasimulatedhomeenvironment